Novartis takes $80M punt on early-stage NASH drug from PliantNovartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline via an $80 million licensing deal Share XNovartis takes $80M punt on early-stage NASH drug from Plianthttps://pharmaphorum.com/news/novartis-takes-80m-punt-on-early-stage-nash-drug-from-pliant/
